Alpha 1 Antitrypsin Deficiency Clinical Trial
Official title:
Effect of a Higher Dose of Alpha-1 Antitrypsin Augmentation Therapy on Lung Inflammation in Subjects With Alpha-1 Antitrypsin Deficiency.
The current treatment of individuals with alpha-1 antitrypsin deficiency (AATD) who develop
lung disease (COPD) is the administration of intravenous purified alpha-1 antitrypsin
(augmentation therapy) at a fixed dose of 60 mg/kg per week. This dose aims at increasing the
deficient AAT serum levels just above a predetermined "safety threshold" of 11 uM. However,
normal levels of AAT are between 25-50 uM.
AAT has shown not only to inhibit lung proteases such as neutrophil elastase, but also to
modulate inflammation. Given that many subjects with AATD who receive augmentation therapy
still have significant lung disease and inflammation, this study will evaluate whether
doubling the dose to 120 mg/kg/week has an effect in decreasing lung inflammation.
Only the dosing of 60 mg/kg /week has received FDA approval. FDA has granted an IND number to
this study to test the higher dose of 120 mg/kg/week.
The study will evaluate systemic (serum) and pulmonary (bronchoscopy samples)markers of
inflammation in 3 phases: standard dose (4 weeks), double dose (4 weeks) and standard dose (4
weeks).
This is a pilot study to test the effect of double dose augmentation therapy with Zemaira
(CSL Behring) on lung inflammation, compared with standard doses of 60 mg/kg/week.
Our hypothesis is that some patients with AATD receiving augmentation therapy at the standard
dose of 60 mg/kg/week continue to have a significant lung inflammation that may lead to
detrimental clinical consequences. This inflammation can be further reduced with higher AAT
dosing.
The study will enroll 20 subjects with AATD and COPD already receiving augmentation therapy
with any brand at standard doses for at least a month. For inclusion and exclusion criteria
see below.
Protocol:
The study will take place over approximately 12 weeks: a month receiving Zemaira at standard
dose (60 mg/kg/week), a month at double dose (120 mg/kg/week) and a month at standard dose
(60 mg/kg/week). The infusions at standard doses will be done at home and infusions with
higher doses will be provided at the study site.
the study involves scheduled blood draws for clinical labs and serum for research samples. At
the end of each phase a bronchoscopy will be performed (3 in total) to obtain research
samples (lung lavage, brushings and endobronchial biopsies).
The first bronchoscopy after receiving 4 weeks of standard augmentation therapy will assess
the "residual" inflammation that may be present despite augmentation therapy. The second
bronchoscopy after double dose augmentation therapy phase will be to assess changes
(decreases) in inflammatory markers. The third bronchoscopy after resuming standard dosing is
to assess if inflammation returned to baseline levels (required for proof of concept).
There will be approximately 9 visits to the study clinic. This study does not include placebo
(no active drug) treatment. Besides blood draws and bronchoscopy, the study will include
questionnaires and lung function testing.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01832220 -
Genomic Research in Alpha-1 Antitrypsin Deficiency
|
N/A | |
| Enrolling by invitation |
NCT00884455 -
Alpha-1 Foundation DNA and Tissue Bank
|